Description
Seeking men and women diagnosed with Multiple sclerosis (MS) within the past 2 years for a study of whether ocrelizumab (study drug) can be used for a period of time rather than permanently and still control your early relapsing MS disease activity.
Overview
Participants in this study can only use the study drug, ocrelizumab, for monoclonal antibody therapy. There are no restrictions for systemic corticosteroids and treatments to help with management of MS symptoms. There will be study visits at least every 3 months over 4 years which may take as long as 4 hours. After a year during which all participants take ocrelizumab, they will then be randomly assigned to get either placebo (looks like ocrelizumab, but contains no medicine) or ocrelizumab.
What we're hoping for
We are studying whether stopping treatment for early relapsing multiple sclerosis (MS) with the monoclonal antibody therapy study drug, ocrelizumab after one or two years of treatment is as effective as continuous treatment in controlling MS.
Additional Information
ClinicalTrials.gov Identifier: NCT05285891